LC-MS/MS raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-04-06 and is reviewed periodically as new material appears.
Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.
Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.
No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.
Melanotan-2 has not received marketing authorisation from major regulatory agencies for any therapeutic indication. Several jurisdictions classify it as a prescription-only medicine or a controlled substance when supplied for human use. Because approved products do not exist, material sold online usually sits outside pharmaceutical supply chains and formal quality oversight. Regulators have issued public notices describing the compound as unapproved. Enforcement varies, and the legal position differs between countries, which complicates any single general statement about its status.
Scientific discussion of Melanotan-2 spans pharmacology, dermatology, and public-health literature. Laboratory studies examine its receptor binding and cellular effects, while clinical reports describe outcomes observed after unregulated use. These two bodies of work differ in rigour and intent. Peer-reviewed trials of the compound as a medicine are limited, so much of the available information comes from case reports and surveillance data. Authors frequently note the gap between experimental findings and real-world use.
Reported observations after unregulated use include shifts in skin pigmentation and, in some accounts, unintended changes to moles and other lesions. Whether these outcomes are causally linked to the compound, and how often they occur, remain open questions because controlled data are scarce. The absence of standardised dosing and verified product purity complicates interpretation. Researchers have called for better surveillance and analytical characterisation of samples obtained outside regulated channels. Conclusions drawn from anecdotal evidence should be treated as provisional.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C50H69N15O9 | Free base; salt forms add to total mass |
| Molecular mass | About 1024 daltons | Calculated for the free base |
| Structural class | Cyclic heptapeptide | Contains D-phenylalanine and norleucine |
| Parent hormone | Alpha-melanocyte-stimulating hormone | Endogenous tridecapeptide of 13 residues |
| Receptor profile | Non-selective melanocortin agonist | Interacts with MC1R, MC3R, MC4R and MC5R |
Melanotan II is a synthetic cyclic heptapeptide that acts as an agonist at melanocortin receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide involved in pigment production. The analogue carries a lactam bridge that constrains the ring and slows enzymatic breakdown relative to the native hormone. In research literature it appears under several abbreviations, and naming conventions are not fully standardized. Published descriptions usually place it within the broader melanocortin agonist family.
Receptor binding at MC1R on melanocytes raises intracellular cyclic AMP and increases expression of tyrosinase and related enzymes. The downstream result is greater synthesis of eumelanin, the dark pigment, without ultraviolet exposure acting as the trigger. The compound is not selective, however, and also engages MC3R, MC4R and MC5R, which are expressed in the central nervous system and elsewhere. That lack of selectivity is the explanation usually offered for effects reported outside pigmentation, including appetite suppression and nausea. Selectivity remains a central theme in comparative studies of related peptides.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
The peer-reviewed record is dominated by small early-phase studies, case reports and pharmacovigilance summaries rather than large randomised trials. Papers typically examine tanning response, receptor selectivity or patterns of reported adverse events. Many note that participants obtained the peptide outside a clinical setting, which limits verification of composition and administered amount. Reported events vary widely, and causality is frequently unclear because the identity and purity of self-sourced material are unknown. Open questions include whether repeated melanocortin receptor stimulation produces cumulative effects, and how often label claims match actual content.
=== East Asia === Some historians believe that saffron came to China with Mongol invaders from Persia. In the field of traditional Chinese medicine, it was first mentioned in the Yinshan zhengyao as an ingredient to treat "internal blazing of heart fire". Shennong Bencaojing, a pharmacopoeia written around 300–200 BC and traditionally credited to the legendary Yan Emperor and the deity Shennong, also mentions saffron among 252 plant-based medical treatments for various disorders. Nevertheless, around the 3rd century AD, the Chinese were referring to it as having a Kashmiri provenance through the Silk Road. According to the herbalist Wan Zhen, "the habitat of saffron is in Kashmir, where people grow it principally to offer it to the Buddha". Wan also reflected on how it was used in his time: "The flower withers after a few days, and then the saffron is obtained. It is valued for its uniform yellow colour. It can be used to aromatise wine." Saffron is a less common food colouring ingredient in local Chinese cuisines than safflower. Since the 1970s, Chinese saffron farming has begun in Maqiao, Shanghai's Minhang district, as well as in Changji, Xinjiang.
=== Asia-Pacific === After the war ended, British Malaya was plunged into a state of emergency as British and Commonwealth forces fought a protracted counter-insurgency war against their former communist-led Malayan Peoples' Anti-Japanese Army ally, who had fought the Japanese occupation and now demanded independence from the British Empire. In British Hong Kong, which had surrendered to Japan in December 1941, civil unrest occurred after Britain rapidly re-established rule at the end of the war. Australia's entry into the Cold War came in 1950, when it rushed combat air and sea forces into the Korean War, two days after the Americans did. Australian Prime Minister Robert Menzies received a hero's welcome in Washington. The ANZUS military alliance with New Zealand and the United States was signed in July 1951; it was a plan for consultation and did not involve military planning like NATO. Public opinion in Australia was intensely hostile to Japan after its wartime atrocities, but Japan was now an ally in the Cold War, so Australia's accepted the very generous soft peace treaty with Japan in 1951. Instead of worrying about a resurgent Japan, Australia now worried more about a possible Chinese threat.
=== Blood oxygen content === The kidneys measure the oxygen content rather than the partial pressure of oxygen in the arterial blood. When the oxygen content of the blood is chronically low, oxygen-sensitive cells secrete erythropoietin (EPO) into the blood. The effector tissue is the red bone marrow which produces red blood cells (RBCs, also called erythrocytes). The increase in RBCs leads to an increased hematocrit in the blood, and a subsequent increase in hemoglobin that increases the oxygen carrying capacity. This is the mechanism whereby high altitude dwellers have higher hematocrits than sea-level residents, and also why persons with pulmonary insufficiency or right-to-left shunts in the heart (through which venous blood by-passes the lungs and goes directly into the systemic circulation) have similarly high hematocrits. Regardless of the partial pressure of oxygen in the blood, the amount of oxygen that can be carried, depends on the hemoglobin content. The partial pressure of oxygen may be sufficient for example in anemia, but the hemoglobin content will be insufficient and subsequently as will be the oxygen content. Given enough supply of iron, vitamin B12 and folic acid, EPO can stimulate RBC production, and hemoglobin and oxygen content restored to normal.
Sources: en.wikipedia.org
== ANA subtypes == ANAs are found in many disorders, as well as some healthy individuals. These disorders include: systemic lupus erythematosus (SLE), rheumatoid arthritis, Sjögren syndrome, scleroderma, polymyositis, dermatomyositis, primary biliary cirrhosis, drug induced lupus, autoimmune hepatitis, multiple sclerosis, discoid lupus, thyroid disease, antiphospholipid syndrome, juvenile idiopathic arthritis, psoriatic arthritis, juvenile dermatomyositis, idiopathic thrombocytopaenic purpura, infection and cancer. These antibodies can be subdivided according to their specificity, and each subset has different propensities for specific disorders.
Australian work relationships begin with a contract, and carry basic rights for fair pay and conditions. Most rights are for "employees" (not the self-employed) who are defined by the reality of systematic unequal bargaining power compared to employers, usually organised in a corporate form. By law, rights are more important than contract terms that employers impose. A contract is a deal entered into by consent, and common law and statute set default rights, such as enough hours, a safe system of work, and sometimes good faith. Further, under the Fair Work Act 2009, the Fair Work Commission sets a national minimum wage, a system of minimum pay scales in modern awards, and oversees collective bargaining between unions and employers. The National Employment Standards also set a floor of rights for a standard maximum 38 hour week, at least 28 to 37 days of annual leave and public holidays, and long service leave. Modern awards set by the Fair Work Commission, for 150 workplace sectors in 2024, must contain terms on working time, consultation before changes, disputes, and flexibility, and usually contain further rights such as higher overtime pay, rest breaks, more holidays, and superannuation to ensure people a decent retirement income. There are also rights to paid parental leave, at a minimum of 20 weeks shared between parents, and the FWC has a duty to end the gender pay gap, given the prior failure to equalise and lengthen parental leave in awards and collective agreements.
Many ectomycorrhizal fungi rely upon mammals for the dispersal of their spores, particularly fungi with hypogeous fruiting bodies. Many species of small mammals are mycophages, eating a wide range of fungi and especially the fruiting bodies. Spores are dispersed either because the fruiting body is unearthed and broken apart, or after ingestion and subsequent excretion. Some studies even suggest that passage through an animal's gut promotes spore germination, although for most fungal species this is not necessary. By spreading the fungal spores, these animals have an indirect effect on plant community structure. Other fruiting bodies are eaten by invertebrates such as mollusks and fly larvae, some of which are even tolerant to the toxic α-amanitin found in death caps. Below ground, nematodes and springtails also consume fungal tissue. The ectomycorrhizal fungus Laccaria bicolor has been found to lure and kill springtails to obtain nitrogen, some of which may then be transferred to the host plant. In one study, eastern white pine inoculated with L. bicolor was able to derive up to 25% of its nitrogen from springtails. Edible fungi are important in societies throughout the world. Truffles, porcinis and chanterelles are known for their culinary and financial importance.
Sources: en.wikipedia.org
== See also == Isotope geochemistry List of elements by stability of isotopes List of nuclides (991 nuclides in order of stability, all with half-lives over one hour) Mononuclidic element Periodic table Primordial nuclide Radionuclide Stable isotope ratio Table of nuclides Valley of stability
Selodenoson ((2S,3S,4R)-5-(6-(cyclopentylamino)-9Hpurin-9-yl)-N-ethyl-3,4-dihydroxytetrahydrofuran-2-carboxamide) Capadenoson (BAY68-4986) Benzyloxy-cyclopentyladenosine (BnOCPA) is an A1R selective agonist.
His first tournament brought immediate reward. Colombia went through the group stage of the 1987 Copa América unbeaten, lost 2–1 to Chile in the semi-final, then beat the hosts Argentina 2–1 at the Monumental on 11 July through Gabriel Jaime Gómez and John Jairo Galeano, Claudio Caniggia replying late before 15,000 spectators. Arnoldo Iguarán finished as the tournament's leading scorer with four goals. The revival coincided with an influx of narcotics money into the domestic game. Atlético Nacional, funded through the Medellín Cartel and its leader Pablo Escobar, retained Colombian internationals who would otherwise have moved abroad and recruited foreign players the league could not previously afford; Maturana, who managed the club from 1987 to 1990, later acknowledged that "the introduction of drug money into soccer allowed us to bring in great foreign players. It also kept our best players from leaving. Our level of play took off." On 31 May 1989 Nacional, fielding Higuita, Andrés Escobar, Leonel Álvarez and Albeiro Usuriaga, beat Olimpia 5–4 on penalties at El Campín to become the first Colombian club to win the Copa Libertadores, supplying Maturana with a ready-made international spine. Colombia were eliminated in the group stage of the 1989 Copa América in Brazil, a 1–0 loss to Paraguay proving decisive despite a goalless draw with the eventual champions. The World Cup qualifiers opened a fortnight later.
Sources: en.wikipedia.org
No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.
Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.
Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.
Major regulatory agencies have not approved it for any indication. Some countries permit it only under prescription frameworks, while others classify it as a controlled substance.